17.70
+3.6(+25.53%)
Currency In USD
Address
1200 Page Mill Road
Palo Alto, CA 94304
United States of America
Phone
650 281 0850
Website
Sector
Healthcare
Industry
Biotechnology
Employees
109
First IPO Date
October 04, 2018
| Name | Title | Pay | Year Born |
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer & President | 1.31M | 1974 |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development | 300,709 | 1972 |
| Mr. John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer & Secretary | 795,799 | 1963 |
| Ms. Almas Qudrat M.Sc. | Chief Quality Officer | 0 | N/A |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer | 0 | N/A |
| Dr. Laurent Ducay Ph.D. | Senior Vice President of Biologics Development & Manufacturing | 0 | N/A |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development & Manufacturing | 0 | N/A |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer | 0 | N/A |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.